Corona Remedies Limited IPO Details

MAINBOARD

Corona Remedies IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.

Pre-issue shareholding stands at 6,11,60,088, which will increase to 6,11,60,088 post-issue.

The Lead Managers for Corona Remedies IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is IIFL Capital Services Limited, Jm Financial Limited, Kotak Mahindra Capital Company Limited. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For detailed information, Refer to the Corona Remedies Limited DRHP.

Corona Remedies IPO Details

Open Date
-
Close Date
-
Listing Date
-
Issue Price
₹0 - ₹0
Face Value
₹10 per share
Lot Size
0
GMP
₹0
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
61160088
Share holding post issue
61160088
Total Issue Size
-
Fresh Issue
-
Offer for Sale
-
DRHP Status
SEBI Approval Received

Corona Remedies IPO Lot Size

ApplicationLotsSharesAmount
To be announced

Corona Remedies IPO Reservation

Promoter Holding

Pre Issue:72.50%
Post Issue:-
Promoter Names:
Dr. Kirtikumar Laxmidas Mehta, Niravkumar Kirtikumar Mehta, Ankur Kirtikumar Mehta

Documents

  ›  Corona Remedies IPO DRHP

Corona Remedies IPO Valuations

ROE:20.36%
ROCE:31.19%
DEBT/EQUITY:0.28
RONW:18.84%
PAT MARGIN:8.92%

Corona Remedies Financial Information

Period Ended31 Dec 202431 Mar 202431 Mar 2023
Assets870.21830.58595.02
Total Income907.241,020.93891.10
Profit After Tax117.8890.5084.93
Net Worth575.05480.41408.52
Total Borrowing61.00134.142.33
Amount in ₹ Crore

About Corona Remedies IPO

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas.

As of December 2024, the company's diverse portfolio includes 67 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).

The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.

The company has two manufacturing facilities, located in the states of Gujarat.

As of December 31, 2024, the company had 88 R&D employees.

Strength Of Corona Remedies IPO

To be announced

Risk Of Corona Remedies IPO

To be announced

Objectives Corona Remedies IPO

To be announced

Company Contact Details

Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej
Ahmedabad, Gujarat, 380059
Phone: +91 79 4023 3000
Email: complianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/

Registrar Contact Details

Name: Bigshare Services Pvt Ltd
Phone: +91-22-62638200
Website: https://ipo.bigshareonline.com/ipo_status.html

Lead Mangers

  1. IIFL Capital Services Limited

    (Past IPO Performance)

  2. Jm Financial Limited

    (Past IPO Performance)

  3. Kotak Mahindra Capital Company Limited

    (Past IPO Performance)

Lead Manager Reports

Read more about Shringar House of Mangalsutra IPO

Comments

© Copyright A2ZIPO. All Rights Reserved